MaxCyte Q3 adjusted EBITDA USD -5.1 million vs. IBES estimate USD -7.99 million

MXCT•2026-11-10

MaxCyte reported Q3 adjusted EBITDA of USD -5.1 million, compared with the IBES estimate of USD -7.99 million.

1. Quarterly results

MaxCyte reported Q3 net income of USD -4.8 million, gross profit of USD 8.5 million and operating expenses of USD 14.5 million. Cash and investments totaled USD 132.7 million.

MaxCyte Q3 adjusted EBITDA USD -5.1 million vs. IBES estimate USD -7.99 million

1. Quarterly results

Related News

Black Diamond Therapeutics Q3 2026 net loss widens 18% to $10 million

EPAM Systems enters $500 million accelerated share repurchase agreement

The Trade Desk: BMO raises target price to $16 from $15

Hyperscale Data sells remaining Bitcoin reserves for about $16 million

Cerebras partners with Bilt to power AI platform and personal assistant